american-journal-of-respiratory-and-critical-care-medicine

American Journal of Respiratory and Critical Care Medicine (american-journal-of-respiratory-and-critical-care-medicine)

Journal positioning

The American Journal of Respiratory and Critical Care Medicine (AJRCCM, the American

Thoracic Society "Blue Journal") is the ATS flagship, publishing high-impact research

across the full respiratory–critical-care–sleep spectrum and across the full evidence

spectrum: definitive clinical trials and cohorts, translational mechanism, and basic

pulmonary, vascular, and immunologic science. Its defining expectation is a

**conceptually important advance in lung biology, respiratory/critical-illness

disease mechanism, or pulmonary/sleep clinical care** — not an incremental

single-center series or a descriptive cohort with no mechanistic or practice-changing

yield. Because it spans bench to bedside, AJRCCM tolerates basic and translational work

that a purely clinical respiratory journal would not. This skill is a **fit /

venue-selection / re-framing** aid; it is not clinical or regulatory advice and does

not replace the journal's current instructions for authors. Before submitting, re-check

the live AJRCCM author instructions.

When to trigger

• The author names AJRCCM or the "Blue Journal" for a respiratory, pulmonary-vascular,

critical-care, or sleep-medicine study and wants a fit/framing check.

• A clinical, translational, or basic-science lung study must be re-framed around a

mechanism or a practice-changing pulmonary/critical-illness question.

• The author is choosing between AJRCCM, The Lancet Respiratory Medicine (clinical/trial

high-impact), and Critical Care Medicine (ICU-focused).

• The author needs the journal's reporting-guideline, registration, and basic/animal-study

expectations spanning bench-to-bedside work.

Scope & topic fit

• Adult and pediatric pulmonary disease: asthma, COPD, ILD/pulmonary fibrosis, cystic

fibrosis, infection, and pulmonary vascular disease (PAH).

• Critical-care and acute respiratory illness: ARDS, mechanical ventilation, acute lung

injury — with mechanistic or outcome rigor.

• Sleep and circadian medicine: sleep-disordered breathing and its physiologic or

outcome consequences.

• Translational and basic lung science: lung development, immunology, epithelial and

endothelial biology, and animal/cell models that illuminate human disease.

• Clinical trials, large cohorts, and biomarker studies with respiratory or

critical-illness endpoints.

• Pulmonary physiology, imaging, and -omics studies that establish a disease mechanism

or a new biological insight.

Method & evidence bar

• Clinical studies must be adequately powered with prespecified, patient-centered

endpoints; trials require prospective registration and the registration number.

• The applicable reporting guideline and checklist are expected: CONSORT for trials,

STROBE for observational work, PRISMA for systematic reviews, ARRIVE for animal studies.

• Translational/basic work must show rigorous controls, biological replication, blinded

and randomized animal experiments where applicable, and reagent/model validation.

• Mechanistic claims need direct causal evidence (perturbation, not correlation alone);

human relevance should be anchored to patient samples or validated models.

• Effect estimates need confidence intervals and absolute as well as relative measures;

causal language must match the design and the species/model studied.

• Sample-size, replication, and statistical-analysis plans must be explicit for both

clinical and laboratory studies.

Structure & house style

• ATS format with a structured abstract and an "At a Glance Commentary" / scientific

knowledge statement; re-check current article types (Original Article, Concise

Clinical Study, etc.) and limits on the live guide.

• The introduction frames the biological or clinical gap; the discussion states the

mechanistic insight or practice implication plainly and bounds overreach.

• A CONSORT/STROBE/PRISMA flow diagram is expected for the relevant clinical design;

animal studies report ARRIVE-aligned design detail.

• Figures must show representative data with statistics, N, and replication; an online

supplement carries full methods, the protocol/SAP, and additional experiments.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and

../../resources/official-source-map.md; start from the ICMJE/EQUATOR and ATS anchors,

then cite the current AJRCCM page you checked.

• Search the live site for "AJRCCM American Thoracic Society instructions for authors"

and follow the current version.

• Re-check article types, abstract and At-a-Glance format, and word/figure/reference limits.
• Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE),

data/code-availability, and protocol/SAP submission.

• Re-check IRB/ethics and consent, animal-care/IACUC approval for laboratory work, ICMJE

authorship and conflict-of-interest disclosure, funding, and AI-use disclosure.

• If the live official instructions conflict with this skill, the official instructions

win.

Pre-submission self-check

• [ ] The study delivers a clear mechanistic insight or practice-changing respiratory/critical-illness finding.
• [ ] Clinical endpoints are prespecified and powered; trials are registered with the number in the manuscript.
• [ ] The correct reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE) is completed and attached.
• [ ] Basic/translational work shows controls, biological replication, and model validation.
• [ ] Mechanistic claims rest on perturbation evidence and are anchored to human relevance.
• [ ] IRB/consent, IACUC (if animal), ICMJE disclosures, and a data-availability statement are prepared.

Common desk-reject triggers

• Single-center descriptive series or registry slice with no mechanism and no practice change.
• Association-only biomarker or -omics studies with no validation cohort or functional follow-up.
• Animal/cell work without disease relevance, replication, or ARRIVE-aligned rigor.
• Missing trial registration, protocol, or the required reporting checklist.
• Narrow ICU-management question better served by an intensive-care journal, or a purely clinical trial with limited mechanistic depth.

Re-routing decision

• High-impact respiratory clinical trial without a mechanistic core → the-lancet-respiratory-medicine.
• ICU-management / organ-support focus over pulmonary biology → critical-care-medicine.
• Perioperative respiratory or sedation/ventilation in surgery → anesthesiology / jama-surgery.
• Broad practice-changing significance beyond pulmonology → general medicine (jama / NEJM / The Lancet in the natural-science bundle).
• Pure basic immunology/cell biology with no lung-disease anchor → a basic-science venue in the natural-science bundle.

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] American Journal of Respiratory and Critical Care Medicine (ATS Blue Journal)
[Specialty tags] <pulmonary / pulmonary-vascular / critical-care / sleep + clinical/translational/basic>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / animal-ARRIVE>
[Method/evidence] <power, mechanism, controls/replication, registration>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / IACUC / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>